Malignant central nervous system tumors among adolescents and young adults (15‐39 years old) in 14 Southern‐Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns. Issue 22 (14th July 2017)

• Record Type: Journal Article
• Authors: Georgakis, Marios K.; Papathoma, Paraskevi; Ryzhov, Anton; Zivkovic‐Perisic, Snezana; Eser, Sultan; Taraszkiewicz, Łukasz; Sekerija, Mario; Žagar, Tina; Antunes, Luis; Zborovskaya, Anna; Bastos, Joana; Florea, Margareta; Coza, Daniela; Demetriou, Anna; Agius, Domenic; Strahinja, Rajko M.; Themistocleous, Marios; Tolia, Maria; Tzanis, Spyridon; Alexiou, George A.; Papanikolaou, Panagiotis G.; Nomikos, Panagiotis; Kantzanou, Maria; Dessypris, Nick; Pourtsidis, Apostolos; Petridou, Eleni T.
• Is Part Of: Cancer. Volume 123:Issue 22(2017)
• Page Start: 4458
• Page End: 4471
• Publication Date: 2017-07-14
• Subjects: adolescents and young adults -- brain tumors -- central nervous system tumors -- epidemiology -- mortality -- outcome -- survival; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.30884
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Unique features and worse outcomes have been reported for cancers among adolescents and young adults (AYAs; 15‐39 years old). The aim of this study was to explore the mortality and survival patterns of malignant central nervous system (CNS) tumors among AYAs in Southern‐Eastern Europe (SEE) in comparison with the US Surveillance, Epidemiology, and End Results (SEER) program. METHODS: Malignant CNS tumors diagnosed in AYAs during the period spanning 1990‐2014 were retrieved from 14 population‐based cancer registries in the SEE region (n = 11, 438). Age‐adjusted mortality rates were calculated and survival patterns were evaluated via Kaplan‐Meier curves and Cox regression analyses, and they were compared with respective 1990‐2012 figures from SEER (n = 13, 573). RESULTS: Mortality rates in SEE (range, 11.9‐18.5 deaths per million) were higher overall than the SEER rate (9.4 deaths per million), with decreasing trends in both regions. Survival rates increased during a comparable period (2001‐2009) in SEE and SEER. The 5‐year survival rate was considerably lower in the SEE registries (46%) versus SEER (67%), mainly because of the extremely low rates in Ukraine; this finding was consistent across age groups and diagnostic subtypes. The highest 5‐year survival rates were recorded for ependymomas (76% in SEE and 92% in SEER), and the worst were recorded for glioblastomas and anaplastic astrocytomas (28% in SEE and 37% in SEER). Advancing age, male sex, and rural residency at diagnosis adversely affected outcomes in both regions. CONCLUSIONS: Despite definite survival gains over the last years, the considerable outcome disparities between the less affluent SEE region and the United States for AYAs with malignant CNS tumors point to health care delivery inequalities. No considerable prognostic deficits for CNS tumors are evident for AYAs versus children. Cancer 2017;123:4458‐71 . © 2017 American Cancer Society . Abstract : Exploiting population‐based data from 14 cancer registries in Southern‐Eastern Europe (1990‐2014), this study calculates mortality and survival rates for malignant central nervous system tumors in the distinct age group of adolescents and young adults (15‐39 years old) and compares them with US Surveillance, Epidemiology, and End Results data (1990‐2012). Despite the survival gains observed during the last decades, the considerable outcome disparities between the less affluent Southern‐Eastern Europe region and the United States for adolescents and young adults with malignant central nervous system tumors point to health care delivery inequalities.